In this article:

Needham Thinks CryoPort’s Stock is Going to Recover

In this article:
In this article:

Needham analyst David Saxon reiterated a Buy rating on CryoPort (CYRXResearch Report) today and set a price target of $41.00. The company’s shares closed last Thursday at $24.17, close to its 52-week low of $21.61.

According to TipRanks.com, Saxon ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.7% and a 19.3% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Alphatec Holdings, and Globus Medical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CryoPort with a $56.33 average price target, representing a 122.6% upside. In a report issued on May 2, SVB Securities also maintained a Buy rating on the stock with a $45.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

CryoPort’s market cap is currently $1.2B and has a P/E ratio of -4.07.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.

Read More on CYRX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed